CFDE Data Portal | Search ITGA9-AS1

	Label	Description
	ITGA9-AS1 associations Collection (Entity type)	Associations for ITGA9-AS1_associations
	ITGA9-AS1 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	ITGA9-AS1 Gene (Entity type)	ENSG00000235257 - ITGA9 antisense RNA 1
	GSE265788 IDH1 inhibition RNA-Directed DNA Polymerase 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE135514 8 V 7 DASATINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE193351 ruxolitinib 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE213588 trametinib NF1 8 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE200982 PLAC8 knockout 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE238213 dopamine 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 7 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS

ITGA9-AS1 associations

Associations for ITGA9-AS1_associations

ITGA9-AS1 associations.tsv

A file from IDG as part of the Harmonizome project

ITGA9-AS1

ENSG00000235257 - ITGA9 antisense RNA 1

GSE265788 IDH1 inhibition RNA-Directed DNA Polymerase 3 v 2 human dn

A Gene Set from LINCS

GSE135514 8 V 7 DASATINIB HUMAN DN

A Gene Set from LINCS

GSE193351 ruxolitinib 1 v 2 human dn

A Gene Set from LINCS

GSE213588 trametinib NF1 8 v 11 human up

A Gene Set from LINCS

GSE200982 PLAC8 knockout 0 v 2 human dn

A Gene Set from LINCS

GSE238213 dopamine 2 v 0 human up

A Gene Set from LINCS

GSE216043 cisplatin 7 v 0 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.